fbpx
Logotipo de Euroespes Health que presenta un cerebro estilizado formado por líneas rojas y azules entrelazadas a la izquierda, que simboliza las "pruebas avanzadas para detectar el Parkinson". Las palabras "euroespes health" están escritas en minúsculas a la derecha sobre un fondo oscuro.
900 922 300

Epigenetics

Among the main projects of the Department of Medical Epigenetics of the EuroEspes International Center for Neurosciences and Genomic Medicine are:

Epigenetic biomarkers

Search for epigenetic biomarkers for the early detection of prevalent diseases (neurodegenerative, cardiovascular and oncological diseases).

Epigenetics R&D

Development of a line of innovative nutraceutical products with epigenetic properties (Epinutraceuticals). These products will improve the levels of epigenetic biomarkers associated with prevalent pathological processes (Alzheimer's, Parkinson's, cardiovascular disorders, etc.).

Epigenetics R&D

Pharmacoepigenetics: Study of the epigenetic changes that occur in genes involved in drug metabolism and their association with the response to such treatments. For example, smoking affects the methylation of CYP1A1, involved in drug metabolism.

Technology and methodology used

 

 

Main contributions

Thanks to the research projects, the Department of Medical Epigenetics has obtained the following achievements:

Global methylation levels are found to be decreased in Alzheimer's disease, Parkinson's disease and vascular dementias.

 

 

 

 

 

 

 

 

Reference: Int J Mol Sci. 2020 Mar; 21(6): 2220. doi: 10.3390/ijms21062220

Global methylation levels increase after treatment with AtreMorine in Parkinson's patients.

 

 

 

 

 

 

 

 

Pending publication.

 

 

 

 

 

 

 

 

 

Nutrients 2020 12(3):747 doi:10.3390/nu12030747.

Recent scientific publications

  • Atremorine treatment regulates DNA methylation in neurodegenerative disorders: epigenetic and pharmacogenetic studies. Martínez-Iglesias O, Naidoo V, Carril JC, Carrera I, Corzo L, Rodríguez S, Alejo R, Cacabelos N, Cacabelos R. CPPM. In press.
  • Epigenetic treatment of neurodegenerative disorders. Martinez Iglesias O and Cacabelos R. Book Chapter in Histone Modifications in Therapy. Elsevier. 2020. Editors: Pedro Castelo-Branco and Carmen Jeronimo.
  • DNA methyltation in neurodegenerative and cerebrovascular disorders. Martinez Iglesias O, Carrera I, Carril JC, Fernández-Novoa L, Cacabelos N, Cacabelos R. IJMS. 2020 Mar23:21(6):2220.
  • Bioactive properties of marine and vegetal nutraceuticals on prevalent diseases. Corza L, Fernández-Novoa L, Carrera I, Martínez O, Rodríguez S, Alejo R and Cacabelos R. Nutrients. 2020 12(3):747.
  • Neuroprotection with natural antioxidants in the context of Neurodegeneration: The epigenetic connection. Carrera I, Martínez O and Cacabelos R. Current Topics in Medicinal Chemistry. 2019 19(32):2999-3011.
  • Pharmacoepigenomic interventions as novel potential treatments for Alzheimer's and Parkinson's Diseases. Teijido O and Cacabelos R. Int J Mol Sci. 2018 19(10):3199.
  • Pharmacogenetics of vascular risk factors in Alzheimer's Disease. Cacabelos R, Mayyazhagan A, Carril JC, Cacabelos P, Teijido O. J Pers Med. 2018 8(1):3
  • Population-based study of risk polymorphisms associated with vascular disorders and dementia. Teijido O, Carril JC, Cacabelos R. Curr Genomics. 2017. 18(5):430-441

 

Leave us your contact information and we will contact you.

Leave us your contact information and we will contact you.